Related Experiment Video
Updated: Jul 14, 2026
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Tissue prognostic markers for adoptive immunotherapy in melanoma
Gaëlle Quereux1, Marie-Christine Pandolfino, Anne-Chantal Knol
1Unit of Skin Oncology, CHU, Place A. Ricordeau, 44035 Nantes, France.
European Journal of Dermatology : EJD
|June 2, 2007
Summary
Tumour immunogenicity impacts adoptive immunotherapy for melanoma. Low expression of immunosuppressive cytokines like TGF-beta and IL-10 in tumour cells correlates with improved patient survival and relapse-free survival.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Adoptive immunotherapy using autologous Tumour Infiltrating Lymphocytes (TIL) is a promising treatment for melanoma.
- Understanding tumour immunogenicity is crucial for predicting response to adoptive immunotherapy.
Purpose of the Study:
- To investigate the correlation between tumour cell expression of specific molecules and patient survival in melanoma treated with autologous TIL therapy.
- To identify potential prognostic markers for adoptive immunotherapy response.
Main Methods:
- Immunohistochemical analysis of lymph node samples from 38 melanoma patients treated with autologous TIL and interleukin-2.
- Evaluation of melanocyte differentiation antigens, MHC molecules, adhesion molecules, and immunosuppressive cytokines (IL-10, TGF-beta, alpha-MSH).
Main Results:
- Low expression of TGF-beta by tumour cells was significantly associated with prolonged relapse-free survival.
- Low expression of TGF-beta, IL-10, ICAM-1, and alpha-MSH correlated with longer overall survival.
Conclusions:
- Weak expression of immunosuppressive cytokines (IL-10, TGF-beta, alpha-MSH) by tumour cells may serve as a favourable prognostic marker.
- Tumour immunogenicity, particularly the level of immunosuppressive cytokines, plays a significant role in the efficacy of adoptive TIL therapy for melanoma.
